COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies

Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Principal Investigator
Nirav Shah
Phase
I/II
Summary
Treat relapsed and/or refractory blood or lymph cancers with a virus (lentivirus) that is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of white blood cell (WBC) that fights infection and eliminates cancer cells.
Description
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL